{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-030996","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.200410+00:00","generated_at":"2026-05-31T10:25:43.546875+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Serina Therapeutics reports Q2 net income $5.2M but warns of going concern doubt","bullets":["Net income $5.2M ($0.61 basic EPS) includes $9.3M non-cash warrant revaluation; operating loss $3.8M.","Cash and restricted cash $6.1M at June 30; $11.2M owed to Juvenescence; substantial doubt about continuing as going concern.","Research and development expenses $1.6M (+$1.1M YoY); G&A $2.3M (+$1.8M YoY) partly from Merger costs.","Partnered with Enable Injections to develop SER-252 (POZ-apomorphine) for Parkinson's; IND planned for 2025.","Appointed Dr. Srini Tenjarla as SVP of CMC & Formulation; presented POZ-lipid immunogenicity data."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-030996","json":"https://secwatch.observer/filing/0001493152-24-030996.json","markdown":"https://secwatch.observer/filing/0001493152-24-030996.md","text":"https://secwatch.observer/filing/0001493152-24-030996.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224030996/0001493152-24-030996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224030996/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:25:43.546875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}